Biosimilar to Rituximab

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instance_of gptkb:biotechnology
gptkbp:administered_by Healthcare professionals
Intravenous infusion
Patients with cancer
gptkbp:approves gptkb:FDA
gptkbp:developed_by gptkb:biotechnology
Various pharmaceutical companies
gptkbp:has_similar_efficacy_to gptkb:Rituximab
https://www.w3.org/2000/01/rdf-schema#label Biosimilar to Rituximab
gptkbp:ingredients gptkb:Oncology
gptkbp:is_available_in Multiple countries
gptkbp:is_biosimilar_to gptkb:Rituximab
gptkbp:is_compared_to Original biologic
Reference product
gptkbp:is_considered Affordable treatment option
Alternative to branded drug
Cost-effective alternative
Effective treatment option
Innovative treatment option
Patient-friendly option
Standard of care
Therapeutic equivalent
gptkbp:is_evaluated_by Safety
Cost-effectiveness
Immunogenicity
Pharmacodynamics
Pharmacokinetics
Efficacy
Long-term outcomes
gptkbp:is_part_of gptkb:health_services
Treatment guidelines
Patient care plans
Pharmaceutical market
Biologics category
Cancer treatment regimens
Monoclonal antibody therapy
gptkbp:is_regulated_by Health authorities
gptkbp:is_subject_to Clinical trials
Market competition
Quality control measures
Post-marketing surveillance
Regulatory approval process
gptkbp:is_used_for gptkb:Non-Hodgkin_lymphoma
gptkb:Chronic_lymphocytic_leukemia
gptkbp:is_used_in gptkb:Oncology
gptkb:Doctor
Autoimmune diseases
Rheumatology
Clinical trials for new indications
Infusion centers
gptkbp:marketed_as Pharmaceutical companies
Different brand names
gptkbp:safety_features gptkb:Rituximab
gptkbp:bfsParent gptkb:Merck_Biosimilars
gptkbp:bfsLayer 6